IDT gBlocks™ Gene Fragments used for Expanding Gene Diversity

Integrated DNA Technologies (IDT), the world leader in oligonucleotide synthesis, has released the latest edition of their DECODED newsletter, which discusses IDT gBlocks™ Gene Fragments and their role in biological factories. Using synthetic biology, biological factories culture genetically modified microorganisms selected to produce a renewable and sustainable source of a broad range of target molecules, including pharmaceuticals and biofuels.

Amyris, an industrial synthetic biology company, has developed a high-throughput pipeline for the rapid testing of thousands of genetically engineered yeast and bacterial strains for production of Biofene®, a renewable diesel replacement, as well as pharmaceuticals, polymers, flavors, and fragrances. Important to this process has been the sourcing and use of gBlocks Gene Fragments, which have provided Amyris a timely solution for engineering new bacterial and yeast strains. Dr Sunil Chandran, the Head of the Automated Strain Engineering group, explains “gBlocks Gene Fragments allow us to get our hands on novel genes or other DNA parts in less than a week”. The use of IDT gBlocks has enabled Dr Chandran and his team to expand the genetic diversity of test strains without any significant time delay, thereby accelerating the critical ‘Design-Build-Test’ cycle.

With high sequence fidelity, gBlocks Gene Fragments can be designed up to 500 base pairs and can be easily introduced to a diverse and innovative range of biological applications. Access the complete article in the 3.1 issue of DECODED.

For more information about how IDT products can facilitate your synthetic biology projects, visit www.idtdna.com. Follow us on twitter @idtdna for real-time updates and insights.

Editors’ notes

About IDT

Integrated DNA Technologies (IDT) is the largest supplier of custom nucleic acids in the world, serving academic, government, and commercial researchers in biotechnology, clinical diagnostics, and pharmaceutical development. IDT's primary business is the manufacture of custom, synthetic DNA and RNA oligonucleotides. Today, IDT synthesizes and ships an average of 36,000 custom oligos per day to more than 86,000 customers worldwide. IDT manufacturing locations include facilities in Coralville, Iowa; San Diego, Calif.; Leuven, Belgium; and Singapore.

For more information visit www.idtdna.com.